Tuberculosis research (tbc)

Developing better vaccines

There is no effective vaccine against TB. BCG, the only existing TB, was developed almost a century ago, but fails to prevent TB effectively. An important part of our research concerns identifying the best bacterial proteins (antigens) that can stimulate the human immune system to contain the infection. Based on these antigens we develop and test new vaccines, including in animal models, which are further evaluated in collaboration with large international research consortia.

The LUMC TB group works both in basic research as well as in the execution of clinical phase I-II trials of new TB vaccines. Thus, our research involves both discovery of relevant antigens, immune cell subsets, classic and alternative immune activation pathways, and the mechanisms by which these inhibit bacteria, as well as clinical testing of new candidate vaccines in the vaccination clinic.